China MedTrip - Frontier Immuno & Cell Therapy

Website

China MedTrip - Frontier Immuno & Cell Therapy We are a leading medical travel company based in Shanghai, China.

Our mission is to assist overseas patients in accessing most advanced and cost - effective medical treatments in China.

Gene Therapies in China: Products & IndicationsAAV gene therapy — RPE65 inherited retinal dystrophyAAV gene therapy — RD...
17/09/2026

Gene Therapies in China: Products & Indications

AAV gene therapy — RPE65 inherited retinal dystrophy
AAV gene therapy — RDH12 inherited retinal disease
ZVS101e — Bietti crystalline retinal dystrophy
EXG102‑031 — Wet age-related macular degeneration
AAV gene therapy — Hemophilia A
Gene-edited autologous hematopoietic stem cell therapy — Transfusion-dependent beta-thalassemia
Vutrisiran (siRNA) — ATTR amyloidosis
Gene-modified therapy — SOD1-mutated ALS
Bopidagene injection (Xinjiuning®) — Moderate to severe Hemophilia B
Notes
Items 1–8: Available only in Boao Lecheng Pilot Zone.
Item 9: Nationwide NMPA approved.
MDT assessment required for eligibility.
CAR-T and stem cell therapies are not gene therapies and excluded.

24-year-old Female from Pakistan Her local doctors said lung transplant was her only option. She was Twenty-four hours ...
05/09/2026

24-year-old Female from Pakistan
Her local doctors said lung transplant was her only option.
She was Twenty-four hours on an oxygen for 24 hours

Her brother, who lives in Germany, found our team.

01/09/2026

Pancreatic cancer takes 90% of its victims within 5 years.

But in one Shanghai hospital, patients are beating those odds — by 2×.

Here's what makes Ruijin Hospital's Pancreatic Cancer Center different:

🔬 **The world's largest pancreatic surgery platform** — 4,000 surgeries/year, 5,000 robotic procedures completed

🤖 **Pioneered robotic pancreatic surgery** — published in BMJ 2026, setting the global standard

💉 **Treatments you won't find anywhere else yet:**
→ mRNA cancer vaccine (30% lower recurrence)
→ TCR-T cells targeting KRAS mutations — a world first
→ Proteomics-guided chemo — right drug, right patient (Nature Medicine cover)

📊 **The result:**
→ 5-year survival: **21.2%** (world avg: 10–13%)
→ After robotic surgery: **34.4%**

---

🟢 **If you or your family has been diagnosed with pancreatic cancer, we can help:**

✅ Assess if surgery is still possible — even when told "unresectable"
✅ Connect you with Prof. Shen Baiyong's team for a Second Opinion
✅ Coordinate your full treatment journey in China — diagnosis, surgery, immunotherapy, follow-up
✅ Handle logistics: visa, translation, accommodation, everything

**Don't wait. Pancreatic cancer moves fast — and so should you.**

📩 DM us
📧 [email protected]
💬 WhatsApp: +86 13721107633 / +86 15212221605

🚨 We waited 40 years. The "undruggable" RAS just got DRUGGED.Yesterday, FDA approved **RASONQUE™ (daraxonrasib / RMC-623...
27/08/2026

🚨 We waited 40 years. The "undruggable" RAS just got DRUGGED.

Yesterday, FDA approved **RASONQUE™ (daraxonrasib / RMC-6236)** — the first-ever RAS(ON) inhibitor for **pancreatic cancer**.

This is a seismic shift for the "King of Cancers."

**But here's what most people don't know: China is already ahead.** 🇨🇳

While the world celebrates RASONQUE, China has been building its own KRAS arsenal — and moving even faster into pancreatic cancer:

🔬 **3 KRAS G12C inhibitors already approved (all homegrown):**
• Fulzerasib (达伯特, Innovent) — Aug 2024
• Garsorasib (安方宁, Inventis) — Nov 2024
• Glecirasib (艾瑞凯, Jacobio) — May 2025

🔥 **HRS-4642 (恒瑞) — KRAS G12D inhibitor:**
• 63.3% response rate in first-line advanced pancreatic cancer
• Published in *Nature Medicine*
• Liposomal formulation — accumulates in tumor for 40+ days
• CDE Breakthrough Therapy Designation granted

🚀 **GFH375 (GenFleet/劲方) — KRAS G12D (ON/OFF) inhibitor:**
• China's FIRST BTD for pancreatic cancer (Feb 2026)
• Also FDA Fast Track for pancreatic cancer
• Phase III registrational trial underway — world's first
• Pioneering combo with anti-cachexia bispecific antibody

💊 **JAB-23E73 (Jacobio) — Pan-KRAS inhibitor:**
• Phase Ib/III launched in China for 1L pancreatic cancer
• ORR 38.5%, DCR 88.5% in 2L+ pancreatic cancer
• Partnership with AstraZeneca expanding globally

**China is not just catching up — in KRAS-targeted pancreatic cancer, China may already be leading.**

At JOYFUL Medical, we connect international patients with China's most advanced treatments — including clinical trials and breakthrough therapies not available anywhere else.

If you or a loved one is fighting pancreatic cancer, there are more doors to knock on than you think.

📩 [email protected]
💬 WhatsApp: +86 13721107633
🌐 www.shjoyfulmed.com

When a family in Singapore received a pancreatic cancer diagnosis, they didn't know where to turn. They found us.We matc...
22/08/2026

When a family in Singapore received a pancreatic cancer diagnosis, they didn't know where to turn. They found us.

We matched them with two of China's leading pancreatic cancer experts:
Professor Xu Qing — expert in cutting‑edge cell therapy and innovative treatments at Mengchao Cancer Hospital.
Professor Shen Boyong — running the largest pancreatic cancer center in the world, with 1,600+ robotic surgeries and access to clinical trials most patients can't reach.

We arranged two private video consultations. The family spoke directly with each doctor — in English. Every question answered. Every concern heard.

One business day later, we delivered a full consultation report with treatment recommendations from both experts.

Your diagnosis deserves more than a Google search. It deserves expert guidance.
JOYFUL Medical — your bridge to China's best cancer care.

📩 DM us **"HOPE"** for a free treatment assessment
📧 [email protected]
🌐 [www.shjoyfulmed.com](https://www.shjoyfulmed.com)
📱 WhatsApp: +86 13721107633 / +86 15212221605

⠀

Address

1st Floor, No. 373, Lane 1555, Jinshajiang West Road
Shanghai
201803

Website

Alerts

Be the first to know and let us send you an email when China MedTrip - Frontier Immuno & Cell Therapy posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category